Harrow Adds Another Piece To Ophthalmology Strategy

Harrow announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis, a serious allergic eye condition that primarily affects children. The announcement is modestly positive for Harrow as it restores availability of an existing ophthalmic product rather than introducing new financial guidance or clinical data. Market impact should be limited, though it may support sentiment around the company’s specialty eye-care portfolio.

Analysis

Harrow announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis, a serious allergic eye condition that primarily affects children. The announcement is modestly positive for Harrow as it restores availability of an existing ophthalmic product rather than introducing new financial guidance or clinical data. Market impact should be limited, though it may support sentiment around the company’s specialty eye-care portfolio.